Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer

Benjamin A Teply, Emmanuel S. Antonarakis

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Purpose of review Understanding the mechanisms by which castration-resistant prostate cancer (CRPC) progresses provides an opportunity to identify novel therapeutic strategies to treat this disease. This understanding has led to approaches to attack prostate cancers androgen axis in unique ways. This review will examine the classes of novel therapies for androgen axis blockade in CRPC, with a particular focus on the unique characteristics of drugs in various stages of clinical development. Recent findings The success of abiraterone and enzalutamide has stimulated multiple investigations into novel approaches to attack the androgen-signaling pathway. Drugs under development include cytochrome P17 inhibitors with 17,20-lyase specificity, androgen receptor antagonists that are active against mutated and constitutively active splice variant forms of the protein, androgen receptor degraders, and bromodomain/ bromodomain extra-terminal inhibitors that prevent chromatin binding of activated receptors. The clinical development of several of these experimental agents is reviewed. Summary Given the unique mechanisms of action for drugs in development, and the possibility that the novel agents may be active in the setting of common resistance mechanisms, treatment options for patients are likely to expand greatly in the coming years. Future studies should prioritize combinations of agents with unique mechanisms of action to optimize outcomes for patients, and should rely on precision-medicine approaches to target known molecular alterations.

Original languageEnglish (US)
Pages (from-to)279-290
Number of pages12
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Volume23
Issue number3
DOIs
StatePublished - Jun 1 2016

Fingerprint

Castration
Androgens
Prostatic Neoplasms
Androgen Receptor Antagonists
Pharmaceutical Preparations
Steroid 17-alpha-Hydroxylase
Precision Medicine
Androgen Receptors
Cytochromes
Chromatin
Protein Isoforms
Therapeutics

Keywords

  • antiandrogens
  • clinical trials
  • mechanisms of action
  • metastatic prostate cancer

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics

Cite this

Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. / Teply, Benjamin A; Antonarakis, Emmanuel S.

In: Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 23, No. 3, 01.06.2016, p. 279-290.

Research output: Contribution to journalReview article

@article{63d984763a4947c5820cfe1a16e2e980,
title = "Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer",
abstract = "Purpose of review Understanding the mechanisms by which castration-resistant prostate cancer (CRPC) progresses provides an opportunity to identify novel therapeutic strategies to treat this disease. This understanding has led to approaches to attack prostate cancers androgen axis in unique ways. This review will examine the classes of novel therapies for androgen axis blockade in CRPC, with a particular focus on the unique characteristics of drugs in various stages of clinical development. Recent findings The success of abiraterone and enzalutamide has stimulated multiple investigations into novel approaches to attack the androgen-signaling pathway. Drugs under development include cytochrome P17 inhibitors with 17,20-lyase specificity, androgen receptor antagonists that are active against mutated and constitutively active splice variant forms of the protein, androgen receptor degraders, and bromodomain/ bromodomain extra-terminal inhibitors that prevent chromatin binding of activated receptors. The clinical development of several of these experimental agents is reviewed. Summary Given the unique mechanisms of action for drugs in development, and the possibility that the novel agents may be active in the setting of common resistance mechanisms, treatment options for patients are likely to expand greatly in the coming years. Future studies should prioritize combinations of agents with unique mechanisms of action to optimize outcomes for patients, and should rely on precision-medicine approaches to target known molecular alterations.",
keywords = "antiandrogens, clinical trials, mechanisms of action, metastatic prostate cancer",
author = "Teply, {Benjamin A} and Antonarakis, {Emmanuel S.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1097/MED.0000000000000254",
language = "English (US)",
volume = "23",
pages = "279--290",
journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
issn = "1752-296X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer

AU - Teply, Benjamin A

AU - Antonarakis, Emmanuel S.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Purpose of review Understanding the mechanisms by which castration-resistant prostate cancer (CRPC) progresses provides an opportunity to identify novel therapeutic strategies to treat this disease. This understanding has led to approaches to attack prostate cancers androgen axis in unique ways. This review will examine the classes of novel therapies for androgen axis blockade in CRPC, with a particular focus on the unique characteristics of drugs in various stages of clinical development. Recent findings The success of abiraterone and enzalutamide has stimulated multiple investigations into novel approaches to attack the androgen-signaling pathway. Drugs under development include cytochrome P17 inhibitors with 17,20-lyase specificity, androgen receptor antagonists that are active against mutated and constitutively active splice variant forms of the protein, androgen receptor degraders, and bromodomain/ bromodomain extra-terminal inhibitors that prevent chromatin binding of activated receptors. The clinical development of several of these experimental agents is reviewed. Summary Given the unique mechanisms of action for drugs in development, and the possibility that the novel agents may be active in the setting of common resistance mechanisms, treatment options for patients are likely to expand greatly in the coming years. Future studies should prioritize combinations of agents with unique mechanisms of action to optimize outcomes for patients, and should rely on precision-medicine approaches to target known molecular alterations.

AB - Purpose of review Understanding the mechanisms by which castration-resistant prostate cancer (CRPC) progresses provides an opportunity to identify novel therapeutic strategies to treat this disease. This understanding has led to approaches to attack prostate cancers androgen axis in unique ways. This review will examine the classes of novel therapies for androgen axis blockade in CRPC, with a particular focus on the unique characteristics of drugs in various stages of clinical development. Recent findings The success of abiraterone and enzalutamide has stimulated multiple investigations into novel approaches to attack the androgen-signaling pathway. Drugs under development include cytochrome P17 inhibitors with 17,20-lyase specificity, androgen receptor antagonists that are active against mutated and constitutively active splice variant forms of the protein, androgen receptor degraders, and bromodomain/ bromodomain extra-terminal inhibitors that prevent chromatin binding of activated receptors. The clinical development of several of these experimental agents is reviewed. Summary Given the unique mechanisms of action for drugs in development, and the possibility that the novel agents may be active in the setting of common resistance mechanisms, treatment options for patients are likely to expand greatly in the coming years. Future studies should prioritize combinations of agents with unique mechanisms of action to optimize outcomes for patients, and should rely on precision-medicine approaches to target known molecular alterations.

KW - antiandrogens

KW - clinical trials

KW - mechanisms of action

KW - metastatic prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84961221318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961221318&partnerID=8YFLogxK

U2 - 10.1097/MED.0000000000000254

DO - 10.1097/MED.0000000000000254

M3 - Review article

VL - 23

SP - 279

EP - 290

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

IS - 3

ER -